Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
AstraZeneca
Colorcon
Express Scripts
McKinsey
McKesson

Last Updated: July 4, 2020

DrugPatentWatch Database Preview

Drugs in Development Information for Ganaxolone


Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

What is the development status for investigational drug Ganaxolone?

Ganaxolone is an investigational drug.

There have been 18 clinical trials for Ganaxolone. The most recent clinical trial was a Phase 2 trial, which was initiated on February 1st 2015.

The most common disease conditions in clinical trials are Epilepsy, Disease, and Seizures. The leading clinical trial sponsors are Marinus Pharmaceuticals, U.S. Army Medical Research and Materiel Command, and University of California, Davis.

There are ninety-nine US patents protecting this investigational drug and nine hundred and seventeen international patents.

Recent Clinical Trials for Ganaxolone
TitleSponsorPhase
RAndomized Therapy In Status EpilepticusMarinus PharmaceuticalsPhase 3
Adjunctive Ganaxolone Treatment (Part A) in TSC Followed by Long-term Treatment (Part B)Marinus PharmaceuticalsPhase 2
Study of Adjunctive Ganaxolone Treatment in Female Children With Protocadherin 19 (PCDH19)-Related Epilepsy (Violet Study)Marinus PharmaceuticalsPhase 3

See all Ganaxolone clinical trials

Clinical Trial Summary for Ganaxolone

Top disease conditions for Ganaxolone
Top clinical trial sponsors for Ganaxolone

See all Ganaxolone clinical trials

US Patents for Ganaxolone

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Ganaxolone   Start Trial Androstane and pregnane steroids with potent allosteric gaba receptor chloride ionophore modulating properties RESEARCH TRIANGLE INSTITUTE (Research Triangle Park, NC) THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (Washington, DC)   Start Trial
Ganaxolone   Start Trial Uses of ganaxolone WISCONSIN ALUMNI RESEARCH FOUNDATION (Madison, WI)   Start Trial
Ganaxolone   Start Trial Controlled release dosage form TRIASTEK, INC. (Nanjing, CN)   Start Trial
Ganaxolone   Start Trial Sugar ester nanoparticle stabilizers St. John's University (Queens, NY)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Ganaxolone

Drugname Country Document Number Estimated Expiration Related US Patent
Ganaxolone Australia 2008265898 2027-06-15   Start Trial
Ganaxolone Canada 2698172 2027-06-15   Start Trial
Ganaxolone European Patent Office 2155204 2027-06-15   Start Trial
Ganaxolone Spain 2589139 2027-06-15   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Johnson and Johnson
Express Scripts
Merck
Colorcon
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.